This

is particularly relevant for new treatments that ser

This

is particularly relevant for new treatments that serve as add-ons to existing chemotherapy regimens, when it is often difficult to show a HRQoL benefit compared with chemotherapy alone, GS-1101 PI3K inhibitor or where OS benefits are not shown. This analysis validates the clinical meaningfulness of PFS as a clinical trial end point. Conclusion The association between PFS and HRQoL reported here supports the use of PFS as a primary endpoint in clinical trials in patients with NSCLC, as it confirms the value of PFS as a patient-relevant endpoint associated with tangible improvements in HRQoL. Supplementary Material Author’s manuscript: Click here to view.(2.1M, pdf) Reviewer comments: Click here to view.(139K, pdf) Acknowledgments Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Suzanne Patel during the preparation of this article. Footnotes Contributors: IG, MP, PMF and SE contributed to the conception and design of the analysis. MP, PMF and SE conducted the analyses and all authors contributed to the interpretation of data. The first draft of the manuscript was written by IG. All authors contributed to critically revising the text for

important intellectual content. All authors provided final approval of this submitted version. Funding: This study was supported by Boehringer Ingelheim. Competing interests: MP, PMF and SE have received consultancy fees from Boehringer Ingelheim. IG is an employee of Boehringer Ingelheim. Provenance and peer review: Not commissioned; externally peer reviewed. Data sharing statement: No additional data are available.
Tricyclic antidepressants have no benefit over placebos in the treatment of adolescent depression1 and are not recommended for treatment in this group by the National Institute for Health and Care Excellence (NICE) guidelines.2 At the time of ethical approval for this study, the European Medicines Agency3 4 recommended that SSRIs in general should not be used for the

treatment of depression in young people, with the exception of fluoxetine where there was some evidence, although limited, of its efficacy. There are additional concerns about the addictive potential of antidepressants AV-951 and many young people and parents would prefer a ‘talking’ therapy in the first instance.5 6 The argument against using medication early is further strengthened by the finding of a large study showing that 21% of moderate to severely depressed adolescents improved with a brief psychosocial intervention before being randomised between medication and treatment as usual.7 There is thus a climate of caution about antidepressant use in general and particularly in adolescents, due to evidence of poor efficacy and high side effects.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>